{"id":403,"date":"2017-06-15T10:08:10","date_gmt":"2017-06-15T10:08:10","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=403"},"modified":"2017-08-29T16:18:28","modified_gmt":"2017-08-29T16:18:28","slug":"nota-informativa-muh-fv-52017","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2017\/06\/15\/nota-informativa-muh-fv-52017\/","title":{"rendered":"Nota Informativa MUH (FV), 5\/2017"},"content":{"rendered":"<table class=\"tablaHome\">\n<tbody>\n<tr>\n<td><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2017\/NI-MUH_FV_05-2017-Uptravi-selexipag.htm\">\u25bc Uptravi (selexipag): contraindicado el uso concomitante con inhibidores potentes de citocromo P450 2C8 (p.ej. gemfibrozilo)<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>\u25bc Uptravi (selexipag): contraindicado el uso concomitante con inhibidores potentes de citocromo P450 2C8 (p.ej. gemfibrozilo)<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,4],"tags":[],"class_list":["post-403","post","type-post","status-publish","format-standard","hentry","category-alertas","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=403"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/403\/revisions"}],"predecessor-version":[{"id":404,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/403\/revisions\/404"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}